R. A. Kyle, Monoclonal gammopathy of undetermined significance. Natural history in 241 cases, Am J Med, vol.64, pp.814-840, 1978.
URL : https://hal.archives-ouvertes.fr/hal-00945713

R. A. Kyle, T. M. Therneau, S. V. Rajkumar, J. R. Offord, D. R. Larson et al., A long-term study of prognosis of monoclonal gammopathy of undetermined significance, N Engl J Med, vol.346, pp.564-573, 2002.

M. V. Dhodapkar, MGUS to myeloma: a mysterious gammopathy of underexplored significance, Blood, vol.128, pp.2599-606, 2016.

R. A. Kyle, D. R. Larson, T. M. Therneau, A. Dispenzieri, S. Kumar et al., Long-term follow-up of monoclonal gammopathy of undetermined significance, New Engl J Med, vol.378, pp.241-250, 2018.

R. A. Kyle and P. R. Greipp, Smoldering multiple myeloma, N Engl J Med, vol.302, pp.1347-1356, 1980.
URL : https://hal.archives-ouvertes.fr/hal-00557757

S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Blade, G. Merlini et al., International myeloma working group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-586, 2014.

E. Bergón and E. Miravalles, Retrospective study of monoclonal gammopathies detected in the clinical laboratory of a Spanish healthcare district: 14-year series, Clin Chem Lab Med, vol.45, pp.190-196, 2007.

R. A. Vescio, J. Cao, C. H. Hong, J. C. Lee, C. H. Wu et al., Myeloma Ig heavy chain V region sequences reveal prior antigenic selection and marked somatic mutation but no intraclonal diversity, J Immunol, vol.155, pp.2487-97, 1995.

S. S. Sahota, R. Leo, T. J. Hamblin, and F. K. Stevenson, Myeloma VL and VH gene sequences reveal a complementary imprint of antigen selection in tumor cells, Blood, vol.89, pp.219-245, 1997.

S. Nair, A. R. Branagan, J. Liu, C. S. Boddupalli, P. K. Mistry et al., Clonal immunoglobulin against lysolipids in the origin of myeloma, N Engl J Med, vol.374, pp.555-61, 2016.

S. Nair, J. Sng, S. Boddupalli, C. Seckinger, A. Chesi et al., Antigen-mediated regulation in monoclonal gammopathies and myeloma, J Clin Invest Insight, vol.3, p.98259, 2018.

A. Bosseboeuf, D. Feron, A. Tallet, C. Rossi, C. Charlier et al., Hepatitis C virus, human herpesvirus 8, and the development of plasma-cell leukemia, J Clin Invest Insight, vol.2, pp.178-187, 2003.

E. Bigot-corbel, M. Gassin, I. Corre, L. Carrer, D. Delaroche et al., Hepatitis C virus (HCV) infection, monoclonal immunoglobulin specific for HCV core protein, and plasma-cell malignancy, Blood, vol.112, pp.4357-4365, 2008.

D. Feron, C. Charlier, V. Gourain, L. Garderet, M. Coste-burel et al., Multiplexed infectious protein microarray immunoassay suitable for the study of the specificity of monoclonal immunoglobulins, Anal Biochem, vol.433, pp.202-211, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-01401584

M. Plummer, C. De-martel, J. Vignat, J. Ferlay, F. Bray et al., Global burden of cancers attributable to infections in 2012: a synthetic analysis, Lancet Glob Health, vol.4, issue.16, pp.30143-30150, 2016.

M. Seifert, R. Scholtysik, and R. Küppers, Origin and pathogenesis of B cell lymphomas, Methods Mol Biol, vol.971, pp.1-25, 2013.

A. Saha and E. S. Robertson, Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes, Clin Cancer Res, vol.17, pp.3056-63, 2011.

S. Franceschi, M. Lise, C. Trépo, P. Berthillon, S. C. Chuang et al., Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European prospective investigation into cancer and nutrition (EPIC), Cancer Epidemiol Biomarkers Prev, vol.20, pp.208-222, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00811971

S. Hermouet, C. A. Sutton, T. M. Rose, R. S. Greenblatt, I. Corre et al., Qualitative and quantitative analysis of human herpesvirus expression in chronic and acute B-cell lymphocytic leukemia and in multiple myeloma, Leukemia, vol.17, pp.185-95, 2003.

A. Bosseboeuf, S. Allain, N. Mennesson, A. Tallet, C. Rossi et al., Proinflammatory state in MGUS and myeloma is characterized by low sialylation of pathogen-specific and other monoclonal and polyclonal immunoglobulin G. Front Immunol, vol.8, p.1347, 2017.

B. Nair, S. Waheed, J. Szymonifka, J. D. Shaughnessy, J. Crowley et al., Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols, Br J Haematol, vol.145, pp.134-141, 2009.

M. Krejci, R. Hajek, T. Buchler, A. Krivanova, A. Svobodnik et al., Simple variables predict survival after autologous transplantation: a single centre experience in 181 multiple myeloma patients, Neoplasma, vol.54, pp.143-151, 2007.

P. Pasqualetti, D. Colantonio, A. Collacciani, R. Casale, and G. Natali, Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications, Panminerva Med, vol.33, pp.93-110, 1991.

L. Wang, F. Jin, Y. Li, J. Sun, J. Zhang et al., IgA type multiple myeloma, clinical features, and prognosis, Chinese Med J, vol.131, pp.1249-50, 2018.

K. Gemenetzi, A. Agathangelidis, A. Papalexandri, A. Medina, E. Genuardi et al., Distinct immunogenetic signatures in IgA versus IgG multiple myeloma, 58th American Society of Hematology (ASH) Annual Meeting & Exposition, 2016.

P. J. Roberts-thomson, D. Y. Mason, and I. Maclennan, Relationship between paraprotein clinical features in IgA polymerization and myeloma, Br J Haematol, vol.33, pp.117-147, 1976.

R. A. Kyle, E. D. Remstein, T. M. Therneau, A. Dispenzieri, P. J. Kurtin et al., Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma, New Engl J Med, vol.356, pp.2582-90, 2007.

F. J. Nooij, A. J. Van-der-sluijs-gelling, C. M. Jol-van-der-zijde, M. J. Van-tol, H. Haas et al., Immunoblotting techniques for the detection of low level homogeneous immunoglobulin components in serum, J Immunol Methods, vol.134, pp.273-81, 1990.

W. Braun and R. Abraham, Modified diffusion blotting for rapid and efficient protein transfer with PhastSystem, Electrophoresis, vol.10, pp.249-53, 1989.

T. Hadar, M. Rahima, E. Kahan, J. Sidi, E. Rakowsky et al., Significance of specific epstein-barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients, J Med Virol, vol.20, pp.329-368, 1986.

E. Levy, M. Margalith, B. Sarov, I. Sarov, C. R. Rinaldo et al., Cytomegalovirus IgG and IgA serum antibodies in a study of HIV infection and HIV-related diseases in homosexual men, J Med Virol, vol.35, pp.174-183, 1991.

M. G. Friedman and N. Kimmel, Herpes Simplex virus-specific serum immunoglobulin a: detection in patients with primary or recurrent herpes infections and in healthy adults, Infect Immun, vol.1, pp.374-381, 1982.

A. E. Wittek, A. M. Arvin, and C. M. Koropchak, Serum immunoglobulin A antibody to varicella-zoster virus in subjects with primary varicella and herpes zoster infections and in immune subjects, J Clin Microbiology, vol.18, pp.1146-1155, 1983.

Y. Urita, K. Hike, N. Torii, Y. Kikuchi, H. Kurakata et al., Comparison of serum IgA and IgG antibodies for detecting helicobacter pylori infection, Int Med, vol.43, pp.548-52, 2004.

G. J. Xu, T. Kula, Q. Xu, M. Z. Li, S. D. Vernon et al., Viral immunology. Comprehensive serological profiling of human populations using a synthetic human virome, Science, vol.348, p.698, 2015.

A. Gonzàlez-quintela, M. R. Alende, R. Gamallo, P. Gonzàlez-gil, S. López-ben et al., Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease, Hepatogastroenterol, vol.54, pp.2121-2127, 2003.

J. I. Cohen, Epstein-Barr virus vaccines, Clin Translat Immunol, vol.4, p.32, 2015.

J. I. Cohen, Vaccine development for epstein-barr virus, Adv Exp Med Biol, vol.1045, pp.477-93, 2018.

F. Fais, F. Ghiotto, S. Hashimoto, B. Sellars, A. Valetto et al., Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors, J Clin Invest, vol.102, pp.1515-1540, 1998.

A. Henriques, A. Rodríguez-caballero, I. Criado, A. W. Langerak, W. G. Nieto et al., Molecular and cytogenetic characterization of expanded B-cell clones from multiclonal versus monoclonal B-cell chronic lymphoproliferative disorders, Haematologica, vol.99, pp.897-907, 2014.

R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto et al., Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood, vol.94, pp.1840-1847, 1999.

T. J. Hamblin, Z. Davis, A. Gardiner, D. G. Oscier, and F. K. Stevenson, Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia, Blood, vol.94, pp.1848-54, 1999.

N. Chiorazzi, K. Hatzi, and E. Albesiano, B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens, Ann N Y Acad Sci, vol.1062, pp.1-12, 2005.

M. Karp and K. Giannopoulos, Antigen stimulation in the development of chronic lymphocytic leukemia, Postepy Hig Med Dosw, vol.67, pp.1204-1217, 2013.

R. Catera, G. J. Silverman, K. Hatzi, T. Seiler, S. Didier et al., Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation, Mol Med, vol.14, pp.665-74, 2008.

C. C. Chu, R. Catera, K. Hatzi, X. J. Yan, L. Zhang et al., Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA, Blood, vol.112, pp.5122-5131, 2008.

L. Myhrinder, A. Hellqvist, E. Sidorova, E. Söderberg, A. Baxendale et al., A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies, Blood, vol.111, pp.3838-3886, 2008.

T. Seiler, M. Woelfle, S. Yancopoulos, R. Catera, W. Li et al., Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells, Blood, vol.114, pp.3615-3639, 2009.

A. Rosén, F. Murray, C. Evaldsson, and R. Rosenquist, Antigens in chronic lymphocytic leukemia-implications for cell origin and leukemogenesis, Semin Cancer Biol, vol.20, pp.400-409, 2010.

M. Williams and M. E. Ariza, EBV positive diffuse large B cell lymphoma and chronic lymphocytic leukemia patients exhibit increased Anti-dUTPase antibodies, Cancers (Basel), vol.10, p.129, 2018.

D. Casabonne, J. Almeida, W. G. Nieto, A. Romero, P. Fernández-navarro et al., Common infectious agents and monoclonal B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults, PLoS ONE, vol.7, p.52808, 2012.

L. Arcaini, M. Merli, S. Volpetti, S. Rattotti, M. Gotti et al., Indolent Bcell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy, Clin Dev Immunol, p.638185, 2012.

K. Hwang, A. M. Trama, D. M. Kozink, X. Chen, K. Wiehe et al., IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria, PLoS ONE, vol.9, p.90725, 2014.

C. Visco, E. Falisi, K. H. Young, M. Pascarella, O. Perbellini et al., Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival, Oncotarget, vol.6, pp.18653-63, 2015.

L. R. Teras, D. E. Rollison, M. Pawlita, A. Michel, J. Brozy et al., Epstein-Barr virus and risk of non-Hodgkin lymphoma in the cancer prevention study-II and a meta-analysis of serologic studies, Int J Cancer, vol.136, pp.108-124, 2015.

D. Casabonne, Y. Benavente, C. Robles, L. Costas, A. E. Gonzalez-barca et al., Aberrant epstein-barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study, Infect Agent Cancer, vol.10, p.5, 2015.

A. Ferrajoli, C. Ivan, M. Ciccone, M. Shimizu, Y. Kita et al., Epsteinbarr virus micrornas are expressed in patients with chronic lymphocytic leukemia and correlate with overall survival, EBioMedicine, vol.2, pp.572-82, 2015.

M. A. Martínez, S. López, C. F. Arias, and P. Isa, Gangliosides have a functional role during rotavirus cell entry, J Virol, vol.87, pp.1115-1137, 2013.

T. M. Therneau, R. A. Kyle, L. J. Melton, D. R. Larson, J. T. Benson et al., Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition, Mayo Clin Proc, vol.87, pp.1071-1080, 2012.

J. P. Bida, R. A. Kyle, T. M. Therneau, . Melton-lj-3rd, M. F. Plevak et al., Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients, Mayo Clin Proc, vol.84, pp.685-93, 2009.

S. Panfilio, D. 'urso, P. Annechini, G. , D. 'elia et al., Regression of a case of multiple myeloma with antiviral treatment in a patient with chronic HCV infection, Leuk Res Rep, vol.2, pp.39-40, 2013.

R. García, A. Linares, M. Mennesson, N. Sanchez-vega, B. Sanchez et al., The role of Hepatitis C virus in the development of multiple myeloma: A case study, 60th Annual Meeting of the American Society of Hematology (ASH), vol.132, p.5592, 2018.

P. Singh, S. Dammeijer, F. Hendriks, and R. W. , Role of Bruton's tyrosine kinase in B cells and malignancies, Mol Cancer, vol.17, p.57, 2018.

J. A. Burger and N. Chiorazzi, B cell receptor signaling in chronic lymphocytic leukemia, Trends Immunol, vol.34, pp.592-601, 2013.

J. S. Pagano, C. B. Whitehurst, and A. G. , Antiviral drugs for EBV, Cancers (Basel), vol.10, p.197, 2018.

D. Verma, J. Thompson, and S. Swaminathan, Spironolactone blocks epstein-barr virus production by inhibiting EBV SM protein function, Proc Natl Acad Sci, vol.113, pp.3609-3623, 2016.

M. H. Tomasson, M. Ali, D. Oliveira, V. , X. Q. Jethava et al., Prevention is the best treatment: the case for understanding the transition from monoclonal gammopathy of undetermined significance to myeloma, Int J Mol Sci, vol.19, p.3621, 2018.

N. J. Weinreb, J. Charrow, H. C. Andersson, P. Kaplan, E. H. Kolodny et al., Effectiveness of enzyme replacement therapy in 1028 patients with type 1 gaucher disease after 2 to 5 years of treatment: a report from the gaucher registry, Am J Med, vol.113, pp.1150-1156, 2002.

N. J. Weinreb, J. Goldblatt, J. Villalobos, J. Charrow, J. A. Cole et al., Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment, J Inherit Metab Dis, vol.36, pp.543-53, 2013.

P. K. Mistry, E. Lukina, B. Turkia, H. Amato, D. Baris et al., Effect of oral eliglustat on splenomagealy in patients with Gaucher disease type 1 : the ENGAGE randomized clinical trial, JAMA, vol.313, pp.695-706, 2015.

M. P. Wasserstein, G. A. Diaz, R. H. Lachmann, M. H. Jouvin, I. Nandy et al., Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months, J Inherit Metab Dis, vol.41, pp.829-867, 2018.

R. H. Lachmann, Treating lysosomal storage disorders: what have we learnt?, J Inherit Metab Dis, vol.43, pp.125-157, 2019.

S. T. Lwin, S. W. Olechnowicz, J. A. Fowler, and C. M. Edwards, Diet-induced obesity promotes a myeloma-like condition in vivo, Leukemia, vol.29, pp.507-517, 2015.

E. V. Pavlova, J. Archer, S. Wang, N. Dekker, J. M. Aerts et al., Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy, J Pathol, vol.235, pp.113-137, 2015.

S. Nair, N. Bar, M. L. Xu, M. Dhodapkar, and P. K. Mistry, Glucosylsphingosine but not saposin C, is the target antigen in Gaucher disease-associated gammopathy

, Mol Genet Metab, vol.129, pp.286-91, 2020.